Researcher
Max Mazzone
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Mazzone Max (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Mazzone Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → 30 Sep 2022
Projects
1 - 10 of 62
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
- Duchenne muscular dystrophy.From1 Jan 2022 → 31 Dec 2022Funding: Nonprofit institution or equivalents
Publications
11 - 20 of 179
- Immunoediting instructs tumor metabolic reprogramming to support immune evasion(2023)
Authors: Max Mazzone
Pages: 118 - + - Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer(2022)
Authors: Federica Cappellesso, Marie-Pauline Orban, Emanuele Berardi, Tessa Ostyn, Tania Roskams, Sabine Tejpar, Baki Topal, Max Mazzone
- PHGDH heterogeneity potentiates cancer cell dissemination and metastasis (vol 605. pg 747, 2022)(2022)
Authors: Margherita Demicco, Anke Vandekeere, Juan Fernandez Garcia, Carla Riera Domingo, David Nittner, Francesca Rizzollo, Panagiotis Karras, dorien Broekaert, Sofie Demeyer, Ayse Bassez, et al.
Pages: E8 - E8 - Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix (vol 4, pg 639, 2022)(2022)
Authors: Carla Riera Domingo, Max Mazzone
Pages: 1084 - 1084 - Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability(2022)
Authors: Max Mazzone
- A cannabidiol aminoquinone derivative activates the PP2A/B55α/HIF pathway and shows protective effects in a murine model of traumatic brain injury(2022)
Authors: Max Mazzone
- Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix(2022)
Authors: Max Mazzone
Pages: 693 - + - PHGDH heterogeneity potentiates cancer cell dissemination and metastasis(2022)
Authors: Margherita Demicco, Ginevra Doglioni, Anke Vandekeere, Alex Cuadros, David Nittner, Francesca Rizzollo, Panagiotis Karras, dorien Broekaert, Sofie Demeyer, Guy Eelen, et al.
Pages: 747 - + - Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia(2022)
Authors: Max Mazzone
- PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index(2022)
Authors: Britt Van Renterghem, Peter Pokreisz, Agnieszka Wozniak, Max Mazzone, Patrick Schöffski
Pages: 568 - 581
Patents
1 - 10 of 10
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)
- Biomarker for anti-tumor therapy (Inventor)
- Combination of p2y6 inhibitors and immune checkpoint inhibitors (Inventor)
- Inhibition of slc4a4 in the treatment of cancer (Inventor)
- Means and methods to treat inflammatory diseases (Inventor)
- Glutamine dehydrogenase inhibitors for use in muscle regeneration (Inventor)
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Podoplanin positive macrophages (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)